Feed excerpt — reported by STAT News
Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and U.S. investors facing an uncertain future.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →